Spoken Alpha
Summit Therapeutics Inc.
Summit Therapeutics develops ivonescimab, a bispecific antibody combining immunotherapy and anti-angiogenesis effects, for treating non-small cell lung cancer and colorectal cancer.
Summit Therapeutics Inc is a Healthcare company operating in Biotechnology with a $13.88B market cap.
Most recent reported earnings: Q3 FY2026 (Oct 18, 2026).
11 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for SMMT.
$ curl https://api.spokenalpha.com/v1/companies/SMMTFAQ
Spoken Alpha indexes SMMT's earnings call transcripts at https://spokenalpha.com/companies/SMMT. Each call links to attributed speakers and parsed analyst Q&A.
Summit Therapeutics Inc. (SMMT) held its most recent earnings call on 2026-02-24, covering fiscal Q4 2025.
Summit Therapeutics Inc. (SMMT) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-10-18 | — | $-0.28 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-22 | $-0.28 | $-0.26 | -7.7% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-06 | $-0.18 | $-0.12 | -45.2% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-02-22 | $-0.21 | $-0.01 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-10-19 | $-0.23 | $-0.04 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-10 | $-0.12 | $-0.09 | -33.3% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-04-28 | $-0.07 | $-0.07 | +0.7% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-02-23 | $-0.06 | $-0.06 | 0.0% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-10-29 | $-0.06 | $-0.05 | -20.0% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $-0.07 | $-0.05 | -40.0% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-04-30 | $-0.05 | $-0.05 | 0.0% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-02-19 | $-0.04 | $-0.05 | +20.0% | $-235.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $-0.03 | — | — | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $-0.02 | — | — | $235.0K | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-1.43 | $-1.43 | 0.0% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-08 | $-0.07 | $-0.07 | 0.0% | $705 | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-0.14 | $-0.14 | 0.0% | $197.0K | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-0.17 | $-0.17 | 0.0% | $193.1K | — | — | EODHD |
| Q1 FY2022 | 2022-05-10 | $-0.22 | $-0.22 | 0.0% | $190.3K | — | — | EODHD |
| Q4 FY2021 | 2022-03-16 | $-0.28 | $-0.28 | 0.0% | $185.6K | — | — | EODHD |
Source: EODHD. SMMT reported actuals as published; sparse fields render as —.